Acadian Asset Management
ANIK icon

Acadian Asset Management’s Anika Therapeutics ANIK Stock Holding History

Acadian Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.79M Hold
606,544
– – 0.01% 563
2025
Q4 		$5.82M Sell
606,544
-26,247
-4% -$251K 0.01% 617
2025
Q3 		$5.94M Buy
632,791
+57,147
+10% +$546K 0.01% 603
2025
Q2 		$6.08M Buy
575,644
+36,030
+7% +$455K 0.01% 538
2025
Q1 		$8.11M Buy
539,614
+63,901
+13% +$1.06M 0.02% 378
2024
Q4 		$7.83M Buy
475,713
+26,929
+6% +$531K 0.02% 408
2024
Q3 		$11.1M Buy
448,784
+5,840
+1% +$151K 0.03% 327
2024
Q2 		$11.2M Buy
442,944
+21,517
+5% +$558K 0.03% 324
2024
Q1 		$10.7M Buy
421,427
+86,436
+26% +$2.09M 0.04% 284
2023
Q4 		$7.59M Sell
334,991
-1,067
-0.3% -$22.1K 0.03% 346
2023
Q3 		$6.25M Buy
336,058
+217,915
+184% +$4.52M 0.03% 373
2023
Q2 		$3.07M Sell
118,143
-55,003
-32% -$1.47M 0.01% 582
2023
Q1 		$4.97M Buy
173,146
+16,879
+11% +$502K 0.02% 455
2022
Q4 		$4.62M Sell
156,267
-4,337
-3% -$123K 0.02% 465
2022
Q3 		$3.82M Buy
160,604
+112,692
+235% +$2.59M 0.02% 479
2022
Q2 		$1.07M Buy
47,912
+6,526
+16% +$146K 0.01% 798
2022
Q1 		$1.04M Buy
41,386
+5,254
+15% +$160K ﹤0.01% 820
2021
Q4 		$1.29M Buy
36,132
+8,483
+31% +$340K ﹤0.01% 770
2021
Q3 		$1.17M Buy
27,649
+16,203
+142% +$667K ﹤0.01% 801
2021
Q2 		$495K Buy
11,446
+9,240
+419% +$394K ﹤0.01% 1161
2021
Q1 		$90K Sell
2,206
-5,598
-72% -$212K ﹤0.01% 1697
2020
Q4 		$353K Sell
7,804
-70,631
-90% -$2.68M ﹤0.01% 1345
2020
Q3 		$2.78M Sell
78,435
-215,459
-73% -$7.78M 0.01% 581
2020
Q2 		$11.1M Buy
+293,894
New +$9.68M 0.05% 310
2019
Q4 		– Sell
-196,854
Closed -$10.8M – 1857
2019
Q3 		$10.8M Buy
+196,854
New +$10.1M 0.05% 328
2019
Q2 		– Sell
-28,517
Closed -$862K – 1765
2019
Q1 		$862K Buy
+28,517
New +$977K ﹤0.01% 943
2017
Q1 		– Sell
-44,086
Closed -$2.16M – 1551
2016
Q4 		$2.16M Sell
44,086
-52,032
-54% -$2.41M 0.01% 581
2016
Q3 		$4.6M Sell
96,118
-47,602
-33% -$2.35M 0.02% 384
2016
Q2 		$7.71M Sell
143,720
-30,051
-17% -$1.42M 0.04% 291
2016
Q1 		$7.77M Buy
173,771
+25,727
+17% +$1.04M 0.04% 313
2015
Q4 		$5.65M Buy
148,044
+10,784
+8% +$413K 0.03% 371
2015
Q3 		$4.37M Sell
137,260
-72,136
-34% -$2.52M 0.02% 418
2015
Q2 		$6.92M Buy
209,396
+31,234
+18% +$1.11M 0.03% 344
2015
Q1 		$7.33M Buy
178,162
+111,429
+167% +$4.5M 0.03% 327
2014
Q4 		$2.72M Buy
66,733
+52,292
+362% +$2.04M 0.01% 492
2014
Q3 		$529K Sell
14,441
-27,366
-65% -$1.18M ﹤0.01% 667
2014
Q2 		$1.94M Sell
41,807
-145,988
-78% -$6.49M 0.01% 505
2014
Q1 		$7.72M Sell
187,795
-16,983
-8% -$631K 0.04% 278
2013
Q4 		$7.82M Buy
204,778
+90,228
+79% +$2.78M 0.04% 281
2013
Q3 		$2.74M Buy
114,550
+105,270
+1,134% +$2.36M 0.02% 402
2013
Q2 		$158K Buy
+9,280
New +$134K ﹤0.01% 701

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's ANIK Position: Q1 2026 in Review

Acadian Asset Management held its Anika Therapeutics (ANIK) position steady in Q1 2026 at 606,544 shares worth $8.79M. The position accounts for 0.01% of the portfolio, ranked #563.

Acadian Asset Management first reported a position in ANIK in Q2 2013 and has held it in 41 quarters since. The position peaked at $11.2M in Q2 2024. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Acadian Asset Management held 606,544 shares of Anika Therapeutics worth $8.79M as of Q1 2026.
  • Acadian Asset Management left its Anika Therapeutics share count unchanged in Q1 2026.
  • Anika Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q1 2026, its #563 holding.
  • Acadian Asset Management first reported a position in Anika Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • Acadian Asset Management's Anika Therapeutics position peaked at $11.2M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.